Personalized immunotherapy shows promise for advanced melanoma in new trial

NCT ID NCT06295159

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the immunotherapy drug nivolumab (Opdivo) given before and after surgery for people with stage III or IV melanoma. The goal is to see if tailoring treatment based on tumor biomarkers leads to better outcomes. About 90 participants will be enrolled at a single center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo)
What this could lead to: If successful, this could show that giving immunotherapy before surgery helps shrink advanced melanoma and improves long-term outcomes.
What could go wrong: This is a mid-stage trial with only 90 participants, so results may not apply to everyone. Immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MELANOMA MELANOMA MELANOMA STAGE III MELANOMA STAGE IV

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.